Posts

Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.

Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said.

Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.

AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.

Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, has named Steven Engle as Chief Executive Officer. Engle joins Gradalis with over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas. He succeeds founder David Shanahan, who will continue as Gradalis’ Board Chair.